Your browser is no longer supported. Please, upgrade your browser.
Settings
MNOV MediciNova Inc. daily Stock Chart
MNOV [NASD]
MediciNova Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own22.50% Shs Outstand29.95M Perf Week0.96%
Market Cap125.49M Forward P/E- EPS next Y-0.31 Insider Trans0.00% Shs Float26.74M Perf Month11.44%
Income-8.50M PEG- EPS next Q-0.08 Inst Own23.10% Short Float1.84% Perf Quarter25.45%
Sales- P/S- EPS this Y-100.00% Inst Trans-0.23% Short Ratio9.53 Perf Half Y16.39%
Book/sh1.28 P/B3.27 EPS next Y3.10% ROA-29.00% Target Price6.00 Perf Year0.24%
Cash/sh0.79 P/C5.32 EPS next 5Y20.00% ROE-34.90% 52W Range2.62 - 5.90 Perf YTD18.03%
Dividend- P/FCF- EPS past 5Y25.70% ROI- 52W High-28.98% Beta0.95
Dividend %- Quick Ratio18.70 Sales past 5Y- Gross Margin- 52W Low59.92% ATR0.19
Employees10 Current Ratio18.70 Sales Q/Q- Oper. Margin- RSI (14)62.04 Volatility4.98% 4.36%
OptionableNo Debt/Eq0.00 EPS Q/Q40.00% Profit Margin- Rel Volume1.52 Prev Close4.22
ShortableYes LT Debt/Eq0.00 EarningsMar 10 AMC Payout- Avg Volume51.59K Price4.19
Recom1.50 SMA204.87% SMA5012.43% SMA20018.12% Volume78,669 Change-0.71%
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Feb-11-16 06:00PM  MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Feb-07-16 06:00PM  MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Jan-27-16 06:18PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis at noodls
06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis GlobeNewswire
Jan-18-16 06:00PM  FDA Grants Rare Pediatric Disease Designation to MediciNovas MN-166 (ibudilast) for the Treatment of Krabbe Disease GlobeNewswire
Jan-13-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe GlobeNewswire
Dec-16-15 02:30PM  MNOV: Positive Interim Safety and Clinical Data Presented at 26th International Symposium on ALS/MND
06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Dec-14-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China GlobeNewswire
Dec-13-15 06:00PM  MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Dec-09-15 05:30PM  MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting GlobeNewswire
Dec-08-15 01:16PM  MEDICINOVA INC Financials
Dec-06-15 06:00PM  MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, California GlobeNewswire
Dec-02-15 07:45AM  Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova Accesswire
Nov-27-15 08:06AM  Is MediciNova, Inc. (MNOV) A Good Stock To Buy? at Insider Monkey
Nov-23-15 09:56AM  Is Timmins Gold Corp (TGD) A Good Stock To Buy? at Insider Monkey
Nov-19-15 06:00AM  MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia GlobeNewswire
Nov-10-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan GlobeNewswire
Nov-09-15 06:00PM  FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital) GlobeNewswire
Nov-04-15 06:00AM  MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida GlobeNewswire
Nov-02-15 03:00PM  MNOV: Presentation on ALS Phase 2 Study in December
Oct-30-15 06:14AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-29-15 05:19PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-13-15 07:00PM  MediciNova to Present Preclinical Data on MN-166 (ibudilast) at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Oct-09-15 06:00AM  MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF GlobeNewswire
Sep-25-15 05:11PM  15 Stocks Moving In Friday's After-Hours Trading
05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-24-15 06:00AM  MediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference GlobeNewswire
Sep-10-15 06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-08-15 11:35AM  MNOV: Phase 2 ALS Trial Expanded
Sep-02-15 07:00PM  MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast) GlobeNewswire
Sep-01-15 06:06AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Aug-25-15 06:04AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-24-15 07:00PM  MediciNova Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Aug-19-15 06:07AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-18-15 07:43PM  MediciNova Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire
05:01PM  Tuesday's After-Hours Movers Led By Analog Devices, Canadian Solar And Weibo
04:00PM  MediciNova Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Aug-03-15 01:45PM  MNOV: Ready to Initiate Phase 2 Trials of MN-001 in IPF and NASH
Aug-01-15 08:09PM  10-Q for MediciNova, Inc. at Company Spotlight
Jul-31-15 06:20AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Jul-30-15 06:07PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Jul-28-15 06:00AM  MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 26th International Symposium on ALS/MND in Orlando, FL: Interim Safety and Clinical Outcomes to be Presented GlobeNewswire
Jul-27-15 02:11PM  MediciNova, Inc. (MNOV)s Stock Jumps on FDA Approval of Second Protocol at Insider Monkey +8.55%
12:36PM  Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More
08:00AM  MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia GlobeNewswire
Jul-21-15 08:00AM  MediciNova Announces Update on Development Plans for MN-001 in IPF GlobeNewswire
Jul-02-15 04:08PM  MEDICINOVA INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Jun-30-15 07:00PM  MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence GlobeNewswire
Jun-24-15 09:00AM  MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting GlobeNewswire
Jun-16-15 06:00AM  MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology GlobeNewswire
Jun-15-15 06:25AM  MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-12-15 06:00AM  MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Jun-03-15 08:00AM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease GlobeNewswire
May-22-15 05:14PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive A
May-13-15 08:11PM  10-Q for MediciNova, Inc. at Company Spotlight
May-12-15 06:16AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
May-11-15 05:46PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
May-07-15 09:07AM  MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at noodls
08:00AM  MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
May-06-15 10:20AM  MNOV: MediciNova's Deep Pipeline Is Meaningfully Undervalued
May-05-15 08:12PM  10-K for MediciNova, Inc. at Company Spotlight
Apr-29-15 06:15AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-23-15 07:21PM  Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting at noodls
07:00PM  Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting GlobeNewswire
Apr-21-15 02:03PM  MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS at noodls
01:45PM  MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Apr-16-15 02:21PM  MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation at TheStreet +41.31%
08:41AM  Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan at noodls
08:30AM  Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan GlobeNewswire
08:12AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis at noodls
08:00AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis GlobeNewswire
Apr-03-15 02:31PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Mar-14-15 01:55AM  MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona at noodls
Mar-13-15 06:08AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Mar-12-15 05:33PM  MEDICINOVA INC Files SEC form 10-K, Annual Report
Mar-02-15 06:00PM  MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona GlobeNewswire
Feb-25-15 06:12PM  MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina at noodls
06:00PM  MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina GlobeNewswire
Feb-16-15 06:18PM  MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS at noodls
06:00PM  MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS GlobeNewswire
Feb-10-15 08:00AM  MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF GlobeNewswire
Feb-03-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of NASH GlobeNewswire
Feb-02-15 06:00PM  MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC GlobeNewswire
Feb-01-15 06:21PM  MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC at noodls
06:00PM  MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC GlobeNewswire
Jan-29-15 06:00PM  MediciNova Receives New Patent Covering MN-029 (denibulin) di-hydrochloride in Japan GlobeNewswire
09:25AM  MediciNova (MNOV) in Focus: Stock Moves 9.5% Higher - Tale of the Tape Zacks
Jan-28-15 08:00AM  MediciNova Announces an Open Investigational New Drug (IND) Application for MN-001 in NASH GlobeNewswire +9.54%
Dec-09-14 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Liver Disorders GlobeNewswire
Dec-02-14 11:00AM  Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off at TheStreet -6.04%
07:41AM  MediciNova (MNOV) Looks Good: Stock Soars 19.3% Zacks
Nov-15-14 07:07PM  10-Q for MediciNova, Inc. Company Spotlight
Nov-14-14 09:01AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-13-14 05:06PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-23-14 07:00PM  U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical Trial of MN-166 (Ibudilast) in ALS GlobeNewswire +8.42%
Oct-22-14 07:00PM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
Oct-17-14 04:00PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -10.73%
Oct-08-14 07:00PM  MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASH GlobeNewswire +10.91%
Oct-06-14 07:00PM  MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston GlobeNewswire +12.67%
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a 2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.